ACRX
$1.02
Acelrx Pharmaceutica
$.01
.99%
ACRX
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.07)
Revenue:  $1.90 Mil
Monday
Nov 15
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ACRX reports earnings?
Beat
Meet
Miss

Where is ACRX's stock price going from here?
Up
Flat
Down
Stock chart of ACRX
Analysts
Summary of analysts' recommendations for ACRX
Score
Grade
Pivots
Resistance
$1.07
$1.05
$1.04

$1.02

Support
$1.01
$0.99
$0.98
Tweet
Growth
Description
AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California.
Peers
StrykerBoston ScientificAbbottBecton, DickinsonResMed3MBaxter InternationalWatersCardiovascular SystemsTeleflex